



## Aldeyra Therapeutics to Participate in Upcoming Conferences

November 9, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 9, 2021-- [Aldeyra Therapeutics, Inc.](#) (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

- **Berenberg US CEO Conference**

Format: Analyst-Hosted Fireside Chat  
Date: Wednesday, November 10, 2021  
Time: 10:00 a.m. ET

Note: A live and recorded webcast of this event will be available on the Investors & Media page of the Company's website at <https://ir.aldeyra.com/>. The recorded webcast will be archived and available for 90 days.

- **Eyecelerator@AAO 2021**

Format: Retina Showcase Presentation  
Date: Thursday, November 11, 2021  
Time: 1:05 p.m. CT (2:05 p.m. ET)

- **Jefferies London Healthcare Conference**

Format: Analyst-Hosted Fireside Chat  
Time: Available On Demand Beginning at 8:00 a.m. GMT (3:00 a.m. ET) Thursday, November 18, 2021  
Note: A webcast of this event will be available on the Investors & Media page of the Company's website at <https://ir.aldeyra.com/>. The recorded webcast will be archived and available for 90 days.

- **Ophthalmology Day at BTIG**

Format: Analyst-Hosted Fireside Chat  
Date: Tuesday, November 30, 2021  
Time: 1:00 p.m. ET

### ***About Aldeyra Therapeutics, Inc.***

Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company's lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company's clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211109006224/en/): <https://www.businesswire.com/news/home/20211109006224/en/>

#### **Corporate Contact:**

Joshua Reed  
Aldeyra Therapeutics, Inc.  
Tel: 781-761-4904 ext. 218  
[jreed@aldeyra.com](mailto:jreed@aldeyra.com)

#### **Investor & Media Contact:**

Scott Solomon  
Sharon Merrill Associates, Inc.  
Tel: 617-542-5300  
[ALDX@investorrelations.com](mailto:ALDX@investorrelations.com)

Source: Aldeyra Therapeutics, Inc.